Jump to main content
Jump to site search


Targeting the protease of West Nile virus

Author affiliations

Abstract

West Nile virus infections can cause severe neurological symptoms. During the last 25 years, cases have been reported in Asia, North America, Africa, Europe and Australia (Kunjin). No West Nile virus vaccines or specific antiviral therapies are available to date. Various viral proteins and host-cell factors have been evaluated as potential drug targets. The viral protease NS2B–NS3 is among the most promising viral targets. It releases viral proteins from a non-functional polyprotein precursor, making it a critical factor of viral replication. Despite strong efforts, no protease inhibitors have reached clinical trials yet. Substrate-derived peptidomimetics have facilitated structural elucidations of the active protease state, while alternative compounds with increased drug-likeness have recently expanded drug discovery efforts beyond the active site.

Graphical abstract: Targeting the protease of West Nile virus

Back to tab navigation

Article information


Submitted
09 Mar 2021
Accepted
17 May 2021
First published
26 May 2021

RSC Med. Chem., 2021, Advance Article
Article type
Review Article

Targeting the protease of West Nile virus

S. Voss and C. Nitsche, RSC Med. Chem., 2021, Advance Article , DOI: 10.1039/D1MD00080B

Social activity

Search articles by author

Spotlight

Advertisements